---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028755"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T01:55:56.515743+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences Q2 net loss $24.5M; discontinues vebicorvir, restructures

## Summary
- Cash and securities of $128.6M as of June 30, 2022, projected to fund operations into first half of 2024.
- Net loss $24.5M ($0.51/share) vs $23.6M ($0.55) in Q2 2021; R&D expense $17.8M, G&A $6.8M.
- Discontinued first-gen core inhibitor vebicorvir (VBR) and restructured to prioritize next-gen candidates 3733 and 4334.
- Initiated Phase 1b trial of next-gen core inhibitor ABI-H3733; initial data expected 2H 2022.
- Introduced new small molecule IFNAR agonist research program for HBV/HDV with oral dosing potential.

## SEC filing metadata
- accession: 0001564590-22-028755
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000156459022028755/0001564590-22-028755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000156459022028755/asmb-8k_20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028755
- JSON: https://secwatch.observer/filing/0001564590-22-028755.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.